Unidentified Speaker Person In my conversations with individuals, it was cited that one of the issues had to do with the Office of Healthcare Affordability and their target requirements or suggestions
Wegovy: Average weight loss in clinical trials: 14%15% Some people lost 20% or even a bit more Takes about a year to see peak results Zepbound: Early studies show 10%15% Some users report fewer stomach issues, so they stay on it more consistently Less long-term data since its newer Realistically, your results depend on your lifestyle, age, metabolism, and if you actually stay on the medication
To understand the comparison, you have to look at their structural origins and their incretin receptor affinities
The dose may need adjusting, or other changes may be needed to stay safe while continuing treatment
However, there was no subsequent performance bout to substantiate whether the reduction in soreness translates to improved performance